STOCK TITAN

Evoke Pharma Inc - EVOK STOCK NEWS

Welcome to our dedicated news page for Evoke Pharma (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evoke Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evoke Pharma's position in the market.

Rhea-AI Summary
Evoke Pharma to present real-world healthcare utilization data on GIMOTI nasal spray at the American College of Gastroenterology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary
Evoke Pharma granted patent for GIMOTI nasal spray, expected to expire in 2029. GIMOTI demonstrates reduction in healthcare resource utilization. GIMOTI can become first-line treatment for diabetic gastroparesis. Commercially available since 2020, prescribed by over a thousand HCPs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
none
-
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) and EVERSANA announced that their abstract on the 'Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients' will be presented at the American College of Gastroenterology annual meeting. The abstract reviews data demonstrating the benefits of GIMOTI, Evoke's FDA-approved nasal formulation of metoclopramide, in reducing healthcare costs for diabetic gastroparesis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
-
Rhea-AI Summary
Evoke Pharma will host a webinar to discuss healthcare resource utilization data related to GIMOTI usage at the DDW 2023 conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.44%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
Evoke Pharma Inc

Nasdaq:EVOK

EVOK Rankings

EVOK Stock Data

4.32M
4.38M
9.65%
29.98%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Solana Beach

About EVOK

evoke pharma is a biotechnology company located in 505 lomas santa fe dr, solana beach, california, united states.